건선 바이오시밀러 시장 보고서(2026년)

Psoriasis biosimilars are biologic drugs developed to closely replicate the structure, function, safety, and efficacy of approved reference biologics for treating moderate to severe psoriasis. These biosimilars offer a more affordable alternative to original biologics, increasing patient access to advanced therapies without compromising quality or clinical outcomes.

The main drug classes in psoriasis biosimilars include TNF-alpha inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are biologics that block tumor necrosis factor-alpha (TNF-a), a key protein driving inflammation in psoriasis. They are used to treat various forms of psoriasis, including plaque, guttate, inverse, and pustular psoriasis, and are administered via subcutaneous, intravenous, oral, and topical routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the psoriasis biosimilars market by increasing the cost of imported biologics, reference molecules, and active pharmaceutical ingredients. Hospital pharmacies and retail distribution channels in regions like North America and Europe, which depend on imports, are most affected. This has led to higher treatment costs and potential delays in patient access. On the positive side, tariffs have encouraged local manufacturing, boosted investment in domestic biosimilar production, and promoted innovation in cost-effective psoriasis therapies.

The psoriasis biosimilars market research report is one of a series of new reports from The Business Research Company that provides psoriasis biosimilars market statistics, including psoriasis biosimilars industry global market size, regional shares, competitors with a psoriasis biosimilars market share, detailed psoriasis biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. This psoriasis biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $8.16 billion in 2025 to $9.08 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to high cost of reference biologics, limited patient access to treatment, growing prevalence of moderate to severe psoriasis, increasing physician awareness and prescriptions, initial approvals of TNF-alpha inhibitors.

The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $13.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to launch of new biosimilars for infliximab, etanercept, and adalimumab, expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, rising adoption of patient assistance programs, growth in clinical trials for novel biosimilars. Major trends in the forecast period include rising adoption of cost-effective psoriasis biosimilars, increased focus on patient access and affordability, growth in subcutaneous and intravenous administration routes, expansion of hospital and retail pharmacy distribution channels, development of targeted therapies for different psoriasis types.

The climbing psoriatic arthritis diagnosis rates are poised to drive the psoriasis biosimilars market forward. Psoriatic arthritis is a persistent autoimmune disorder sparking joint and skin swelling, commonly in those with psoriasis backgrounds. Diagnosis rates are up, especially from refined screening in psoriasis patients that catches early, faint joint signs once overlooked. Psoriasis biosimilars ease psoriatic arthritis with budget-friendly biologic stand-ins, curbing joint flare-ups and skin issues. For example, in August 2025, the National Psoriasis Foundation (NPF), a US patient advocacy non-profit, stated psoriatic arthritis hits about 1 in 3 psoriasis cases, impacting 2.4 million Americans; over 15% of psoriasis sufferers have undetected psoriatic arthritis, underscoring better detection amid gaps. Thus, the rising psoriatic arthritis diagnoses are fueling the psoriasis biosimilars market.

Leading firms in the psoriasis biosimilars market are rolling out fresh options like biosimilars for plaque psoriasis to widen access, trim expenses, and lift results. Biosimilars for plaque psoriasis offer economical, near-identical swaps for reference biologics tackling the ongoing skin autoimmune issue with red, flaky patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based generics and biosimilars specialist, debuted the Pyzchiva autoinjector-the inaugural commercial ustekinumab biosimilar auto-device. Approved for adult plaque psoriasis, psoriatic arthritis, and Crohn's, plus kids over six (60+ kg) with plaque psoriasis, it boosts compliance and life quality via precise auto-dosing, less pain, slim profile, and easy storage for hassle-free self-use.

In September 2023, Sandoz Group AG, a Switzerland pharma player, teamed with Samsung Bioepis to market the SB17 (ustekinumab) biosimilar. This alliance taps both strengths to deliver the plaque psoriasis treatment across Europe and North America. It broadens reach to quality, affordable immunology care, cementing Sandoz's biosimilars dominance. Samsung Bioepis is a South Korea biopharma focused on biosimilars, including plaque psoriasis therapies.

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the psoriasis biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psoriasis Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses psoriasis biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriasis biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The psoriasis biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: TNF-Alpha Inhibitors; Infliximab; Etanercept; Adalimumab; Other Biosimilars
• 2) By Disease Type: Plaque Psoriasis; Guttate Psoriasis; Inverse Psoriasis; Pustular Psoriasis
• 3) By Route Of Administration: Subcutaneous; Intravenous; Oral; Topical
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars; Fusion Protein Biosimilars
• 2) By Infliximab: Remicade Biosimilars; CT-P13 Biosimilars
• 3) By Etanercept: Enbrel Biosimilars; SB4 Biosimilars
• 4) By Adalimumab: Humira Biosimilars; ABP 501 Biosimilars
• 5) By Other Biosimilars: Ustekinumab Biosimilars; Secukinumab Biosimilars
• Companies Mentioned: Pfizer Inc.; Amgen Inc.; Sandoz Group AG; Fresenius Kabi AG; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Samsung Bioepis Co. Ltd.; Zydus Lifesciences Ltd.; Celltrion Inc.; Bio-Thera Solutions Ltd.; Coherus BioSciences Inc.; mAbxience S.A.; Alvotech hf.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Psoriasis Biosimilars Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Psoriasis Biosimilars Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Psoriasis Biosimilars Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Psoriasis Biosimilars Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Cost-Effective Psoriasis Biosimilars
  • 4.2.2 Increased Focus On Patient Access And Affordability
  • 4.2.3 Growth In Subcutaneous And Intravenous Administration Routes
  • 4.2.4 Expansion Of Hospital And Retail Pharmacy Distribution Channels
  • 4.2.5 Development Of Targeted Therapies For Different Psoriasis Types

5. Psoriasis Biosimilars Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Online Pharmacies
• 5.4 Dermatology Clinics
• 5.5 Specialty Care Centers

6. Psoriasis Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Psoriasis Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Psoriasis Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Psoriasis Biosimilars Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Psoriasis Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Psoriasis Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Psoriasis Biosimilars Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Psoriasis Biosimilars Market Segmentation

• 9.1. Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
• 9.2. Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
• 9.3. Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Subcutaneous, Intravenous, Oral, Topical
• 9.4. Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.5. Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
• 9.6. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Remicade Biosimilars, CT-P13 Biosimilars
• 9.7. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Enbrel Biosimilars, SB4 Biosimilars
• 9.8. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Humira Biosimilars, ABP 501 Biosimilars
• 9.9. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ustekinumab Biosimilars, Secukinumab Biosimilars

10. Psoriasis Biosimilars Market Regional And Country Analysis

• 10.1. Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Psoriasis Biosimilars Market

• 11.1. Asia-Pacific Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Psoriasis Biosimilars Market

• 12.1. China Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Psoriasis Biosimilars Market

• 13.1. India Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Psoriasis Biosimilars Market

• 14.1. Japan Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Psoriasis Biosimilars Market

• 15.1. Australia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Psoriasis Biosimilars Market

• 16.1. Indonesia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Psoriasis Biosimilars Market

• 17.1. South Korea Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Psoriasis Biosimilars Market

• 18.1. Taiwan Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Psoriasis Biosimilars Market

• 19.1. South East Asia Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Psoriasis Biosimilars Market

• 20.1. Western Europe Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Psoriasis Biosimilars Market

• 21.1. UK Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Psoriasis Biosimilars Market

• 22.1. Germany Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Psoriasis Biosimilars Market

• 23.1. France Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Psoriasis Biosimilars Market

• 24.1. Italy Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Psoriasis Biosimilars Market

• 25.1. Spain Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Psoriasis Biosimilars Market

• 26.1. Eastern Europe Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Psoriasis Biosimilars Market

• 27.1. Russia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Psoriasis Biosimilars Market

• 28.1. North America Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Psoriasis Biosimilars Market

• 29.1. USA Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Psoriasis Biosimilars Market

• 30.1. Canada Psoriasis Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Psoriasis Biosimilars Market

• 31.1. South America Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Psoriasis Biosimilars Market

• 32.1. Brazil Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Psoriasis Biosimilars Market

• 33.1. Middle East Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Psoriasis Biosimilars Market

• 34.1. Africa Psoriasis Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Psoriasis Biosimilars Market Regulatory and Investment Landscape

36. Psoriasis Biosimilars Market Competitive Landscape And Company Profiles

• 36.1. Psoriasis Biosimilars Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Psoriasis Biosimilars Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Psoriasis Biosimilars Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Psoriasis Biosimilars Market Other Major And Innovative Companies

• STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

38. Global Psoriasis Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Psoriasis Biosimilars Market

40. Psoriasis Biosimilars Market High Potential Countries, Segments and Strategies

• 40.1 Psoriasis Biosimilars Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Psoriasis Biosimilars Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Psoriasis Biosimilars Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer